In the case of BCP-ALL, two CD19-targeted strategies are available; one utilizing bispecific monoclonal antibodies targeting T-cells and CD19-positive B-lineage cells (blinatumomab), and the other chimeric antigen receptor T-cells (CAR-T). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.